Pityriasis rosea during etanercept therapy.
Multiple bioengineered agents has been recently developed to attack other parts of the immune/inflammatory system, achieving therapeutic implications for dermatologic diseases. On the other side, each new therapy has the potential for adverse cutaneous reactions. We present herein the first two cases of Gibert's pityriasis rosea occurring during etanercept therapy and discuss possible links between this common, etiologically still unexplained exanthema and anti-tumor necrosis factor-alpha drugs.
Guarneri
C
C
Department of Social Territorial Medicine, Section of Dermatology, University of Messina, Italy. cguarneri@unime.it
Polimeni
G
G
Nunnari
G
G
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D017515:Pityriasis Rosea / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept